ClinicalTrials.gg
Active, not recruitingNCT06772597Updated Nov 13, 2026

A Study of Setmelanotide in Patients With Prader-Willi Syndrome

A Phase 2 interventional study of Setmelanotide in Prader-Willi Syndrome, Obesity and Hyperphagia, sponsored by Rhythm Pharmaceuticals, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
6 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
35th of 58
18 · median 23
Started
2025
with 4 others
Phase 2
17 of 69
1 open now
Primary completion
2026-11
later than 3 of 13 live
Registered
62nd of 69
by date
Lead sponsor
3 of 69
Rhythm Pharmaceuticals, Inc.

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 35th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2025, is one of 17 in phase 2, reaches primary completion later than 3 of the 13 other live ones, and was the 62nd registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 6 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 52 weeks.

03

Conditions studied

  • Prader-Willi Syndrome
  • Obesity
  • Hyperphagia

Keywords

  • melanocortin 4 receptor (MC4R), MC4R agonist
04

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Confirmed diagnosis of Prader-Willi Syndrome (PWS)
  • Age 6 to 65
  • ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th Percentile for age and sex
  • Agree to use a highly effective form of and follow the study contraception requirements throughout study duration and for 90 days after.
  • Patient and/or guardian is able to communicate well with the Investigator, understand and comply with the requirements of the study, and understand English and sign the written .

Exclusion Criteria:

  • Use of weight modulating medications
  • Abnormal , , AST, and values
  • Current, pulmonary, cardiac, metabolic, or oncologic disease considered severe enough to interfere with the trial and/or confound the results.
  • Participation in any clinical trial with an drug/device within 3 months or 5 half-lives, whichever is longer, prior to the first trial dose
  • to setmelanotide
  • Diagnosis of severe psychiatric disorders
  • Pregnant and/or breastfeeding

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Setmelanotide (Open-label)

    Drug: Setmelanotide

Interventions

  • Setmelanotide (daily subcutaneous injection)

    Also known as: Imcivree

06

What researchers measure

Primary outcomes

  1. Frequency and severity of adverse events (AEs)

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Proportion of patients who achieve 5% reduction in BMI

    Time frame: Baseline to Week 52

  2. Mean percent change in BMI

    Time frame: Baseline to Week 52

  3. Mean percent change in BMI and weight in patients ≥18 years of age

    Time frame: Baseline to Week 52

  4. Mean change in BMI Z-Score and BMI % of 95th percentile

    Time frame: Baseline to Week 52

  5. Proportion of patients who achieved 5% reduction in weight from Baseline in patients ≥18 years of age and who achieved ≥0.2 reduction in BMI Z-score in patients <18 years of age

    Time frame: Baseline to Week 52

  6. Mean change in the weekly average of the Prader-Willi Syndrome Food Problem Diary (PWS-FPD) total score

    Time frame: Baseline to Week 52

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Nov 2026, 19 months.

Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's 19 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2027 → Oct 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 13, 2025
StartActual
Mar 4, 2025
Primary completionActual
Nov 3, 2026was Oct 2026
CompletionEst.
Oct 30, 2030was Oct 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Nov 3, 2026 (actual)
Nov 13, 2026
Study completion
Oct 31, 2027→Oct 30, 2030
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Oct 31, 2026→Nov 3, 2026 (now actual)
    Study completion Oct 31, 2027→Oct 30, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06772597
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Mar 4, 2025
Primary completion
Nov 3, 2026
Completion
Oct 30, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion